A case of Streptococcus intermedius empyema
| Autor: | Kurt A. Wargo, Steven A Higginbotham, Victoria J McConnell |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Chronic bronchitis
medicine.medical_specialty Exacerbation Staphylococcus 030204 cardiovascular system & hematology Streptococcus intermedius 030226 pharmacology & pharmacy Tazobactam 03 medical and health sciences 0302 clinical medicine Fatal Outcome Community-acquired pneumonia Medicine Humans Pharmacology (medical) Abscess Empyema Aged 80 and over biology business.industry Staphylococcal Infections biology.organism_classification medicine.disease Surgery Community-Acquired Infections Pneumonia Female business medicine.drug |
| Zdroj: | The Annals of pharmacotherapy. 40(6) |
| ISSN: | 1060-0280 |
| Popis: | Objective: To report a case of empyema caused by Streptococcus intermedius as a complication of community-acquired pneumonia (CAP). Case Summary: An 85-year-old woman with a history of chronic obstructive pulmonary disease, asthma, heart failure, and hypothyroidism developed empyema as a result of 2 episodes of CAP and an acute exacerbation of chronic bronchitis within the past 2 months. Therapy with intravenous levofloxacin 750 mg every 48 hours was initiated. Culture results of the empyema fluid yielded pure growth of a rarely encountered microorganism, S. intermedius. Intravenous piperacillin/tazobactam 3.375 g every 6 hours was added to the antimicrobial therapy at that time. However, cultures continued to show S. intermedius. Surgical decortication was unsuccessful, and the patient died after a 30 day hospital stay. Discussion: Early, appropriate antimicrobial therapy is the mainstay of CAP treatment. Although rare, empyema or thoracic abscess can occur despite this therapy, due to mucosal changes caused by CAP. Historically, antimicrobial therapy used to treat organisms that typically cause CAP also has activity against S. intermedius. However, growth of this microorganism and failure to respond to therapy should alert clinicians to the possibility of empyema or abscess formation. Conclusions: Despite historical in vitro susceptibility data of S. intermedius, antimicrobial therapy may be ineffective, and more extreme measures may be needed to achieve a successful outcome. Early, appropriate antimicrobial therapy needs to remain the mainstay of the treatment of CAP in an attempt to prevent fatal complications such as this from occurring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|